protocolSection identificationModule nctId: NCT06291467, orgStudyIdInfo id: RECHMPL23_0121, briefTitle: Plasma Beta-endorphin Levels and Suicidal Behavior, acronym: BEST, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2026-03, completionDateStruct date: 2026-03, studyFirstPostDateStruct date: 2024-03-04, lastUpdatePostDateStruct date: 2024-03-04, sponsorCollaboratorsModule leadSponsor name: University Hospital, Montpellier, class: OTHER, collaborators name: Institut de Génomique Fonctionnelle (IGF) de Montpellier, descriptionModule briefSummary: It is an interventional research, monocentric, which involves only minimal risks and constraints.Psychological pain is closely associated with suicidal ideation (SI) and suicidal behavior, regardless of the severity of the depression. The psychological pain being regulated by the opioidergic system, it seems that a dysfunction of this system exists in suicidal attempters. The aim of this study is to explore the association between levels of β-endorphin and suicidal behavior.The research team will measure plasma levels of β-endorphin in patients hospitalized for suicide attempt (SA) within 72 hours and compare them to those of patients hospitalized for current major depressive episode (EDC) without any lifetime history of SA. In order to follow the kinetics of β endorphin levels, The research team will carry out two measurements: at inclusion and on day 7 (+/- 2 days) of inclusion.The main objective is to compare plasma β-endorphin levels in patients hospitalized following a recent SA (≤72 hours) and in patients hospitalized for an EDC without lifetime history of SA., conditionsModule conditions: Suicide, conditions: Depression, conditions: Beta Endorphin, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 104, type: ESTIMATED, armsInterventionsModule interventions name: Blood samples, interventions name: questionnaires, outcomesModule primaryOutcomes measure: Comparison of plasma β-endorphin levels between patients with recent suicide attempt (≤ 72 hours) vs. patients with current major depressive episode without any lifetime history of suicide attempt., secondaryOutcomes measure: - The kinetics of β-endorphin levels between two measurement points (inclusion and D7+/-2 days) in patients with recent suicide attempt (≤ 72 hours) vs. patients with current major depressive episode without any history of suicide attempt., secondaryOutcomes measure: The level of depression in the last week before inclusion assessed by a self-administered questionnaire (MADRS), secondaryOutcomes measure: The level of depression in the last week before inclusion assessed by a self-administered questionnaire (QIDS-16), secondaryOutcomes measure: To assess the association between β-endorphin levels and and Suicidal ideation and history of suicidal behavior in the last week before inclusion,, secondaryOutcomes measure: To assess the association between β-endorphin levels and Anhedonia, secondaryOutcomes measure: To assess the association between β-endorphin levels and Current psychological and physical pain as well as usual and maximum over the 15 days before inclusion, secondaryOutcomes measure: To assess the association between β-endorphin levels and Anxiety,, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University hospital, city: Montpellier, zip: 34295, country: France, contacts name: Jessica DALAUDIERE, role: CONTACT, email: jessica.dalaudiere@chu-montpellier.fr, geoPoint lat: 43.61092, lon: 3.87723, hasResults: False